Clinical Trial Update: Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas [EARLY_Phase 1]

View source ↗

Summary

This early-phase 1 trial investigates vemurafenib in pediatric patients with recurrent/refractory BRAFV600E-mutant gliomas and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Vemurafenib (vemurafenib)

Snippet

Sponsor: University of California, San Francisco | Conditions: Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas | EARLY_Phase 1 | Status: COMPLETED